Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling

High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Hiroo Katsuya, Haruhiko Sano, Haruna Sano, Tatsuya Mihashi, Chiho Nakashima, Keita Kai, Shinya Kimura
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-02-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	immune checkpoint inhibitor (ICI) tumour mutational burden (TMB) malignant phyllodes tumor of the breast comprehensive genomic profiling (CGP) microsatellite instability
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549452/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!